Table 4.
Desvenlafaxine compared to placebo and venlafaxine: adjusted mean change in HAMD17 from baseline in six 8-week randomized controlled trials
| Level of evidence | Once daily drug dose (mg) (n) | Adjusted mean change from baseline | p-value vs placebo | Reference |
|---|---|---|---|---|
| 2 | DVS 100 (114) | –10.60 | p = 0.0038 | Demartinis et al37 |
| DVS 200 (116) | –9.63 | p = 0.0764 | ||
| DVS 400 (113) | –10.74 | p = 0.0023 | ||
| Placebo (118) | –7.65 | |||
| 2 | DVS 200 (121) | –12.6 | p = 0.002 | Septien-Velez et al38 |
| DVS 400 (124) | –12.1 | p = 0.008 | ||
| Placebo (124) | –9.3 | |||
| 2 | DVS 100–200 (120) | –9.6 | p = 0.277 | Liebowitz et al48 |
| Placebo (114) | –8.6 | |||
| 2 | DVS 50 (158) | –11.5 | p = 0.018 | Liebowitz et al47 |
| DVS 100 (157) | –11.0 | p = 0.065 | ||
| Placebo (159) | –9.5 | |||
| 2 | DVS 50 (145) | –14.4 | p < 0.001 | Boyer et al46 |
| DVS 100 (126) | –14.9 | p < 0.001 | ||
| Placebo (138) | –11.5 | |||
| 2 | DVS 200–400 (226) | –14.21 | p < 0.001 | Lieberman et al39 (pooled analysis) |
| VEN ER 75–150 (127) | –14.26 | p = 0.001 | ||
| VEN ER 150–225 (115) | –14.56 | p < 0.001 | ||
| Placebo (245) | –11.87 |
Abbreviations: DVS, desvenlafaxine; VEN ER, venlafaxine ER.